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Sa˜o Paulo, SP, BrazilObjective. To determine graft patency and limb preservation after allograft bypass grafting to infrapopliteal arteries for
different allograft materials.
Design. Meta-analysis of case series that used survival analysis to describe outcomes.
Methods. Studies published from 1982 through 2003 were identified from electronic databases and pertinent original
articles. Four series of cryopreserved arterial allografts, 10 series of cryopreserved vein allografts, three series of cold-storaged
vein allografts, and 16 series of umbilical-cord vein allografts were included in separate random-effects meta-analyses.
Results. A graphical display of pooled survival curves of graft patency showed cold-storaged veins to have the best outcome
in the first 4 years, followed by cryopreserved arteries, umbilical-cord veins, and cryopreserved veins. The respective 5-year
pooled patency were 24, 21, 30, and 19%. For foot preservation, the best outcome was achieved with cryopreserved arteries
followed by cryopreserved veins, umbilical-cord veins, and cold-storaged veins. A reference meta-analysis of
polytetrafluoroethlylene grafts occupied the top position for graft patency and the second position for foot preservation.
Conclusion. In leg revascularisation for critical ischaemia, graft patency is poor for allografts generally, but using
peripheral allografts in repeat attempts at revascularisation is a valid strategy to prevent major amputation. A role for
umbilical-cord vein allografts remains uncertain.Keywords: Allograft; Bypass; Meta-analysis.Introduction
There is no consensus about the alternative graft that
should be used for infrapopliteal bypass grafting
when the great saphenous vein is unavailable. A
policy of using all-autologous tissue grafts may yield
superior graft patency rates in the long term, but this is
achieved at the cost of harvesting veins from distant
sites and constructing composite grafts. In contrast,
the use of nonautologous grafts reduces the need for
multiple incisions at the cost of decreased durability
and increased risk of graft-related complications.
Polytetrafluoroethylene (PTFE) grafts have been
used regularly for more than two decades. Whening author. Dr. M. Albers, Rua Ministro Godo´i, 1584,
-001 Sa˜o Paulo, SP, Brazil.
: albersm@uol.com.br (M. Albers).
0462+ 11 $35.00/0 q 2004 Elsevier Ltd. All rights reserplaced distally into an infrapopliteal artery, such grafts
often include an adjunctive procedure and may
require permanent anticoagulation. Despite the pro-
ven success of the umbilical-cord vein allograft (UVA)
in above-knee femoropopliteal revascularisation,1 the
use of this allograft as a femorocrural bypass has
declined markedly. Greater attention has been given to
allografts sourced from peripheral vessels and sub-
mitted to cryopreservation. Easy handling, increased
pliability and a higher resistance to infection have
been cited as distinct advantages of peripheral
allografts over UVAs and PTFE grafts, but immuno-
logical rejection is a major limitation.
Despite the conflicting results reported for the
cryopreserved vein allograft (CVA),2,3 there is reason
for moderate optimismwith the cryopreserved arterial
allograft (CAA)4–7 and the modern UVA.8 Sparse
studies with the cold-storaged vein allograft (CSVA)Eur J Vasc Endovasc Surg 28, 462–472 (2004)
doi:10.1016/j.ejvs.2004.08.009, available online at http://www.sciencedirect.com onved.
Allograft Bypass Grafting 463are also encouraging.9–12 Because of uncertainty
regarding allograft bypass grafting to the infrapopli-
teal arteries, meta-analysis was used to assess long-
term graft patency and foot preservation for each
allograft material separately.Materials and MethodsStudy identification
Two undergraduate medical students with no pre-
vious experience in meta-analysis and the senior
author (M.A.) searched articles in PUBMED, LILACS
and OVID databases. Excerpta Medica Surgery, vascular
surgery section, was reviewed manually. The search
covered January 1980 through December 2003 and
combined the primary descriptors bypass, revascular-
isation and arterial reconstruction with the secondary
descriptors allograft, homograft, umbilical cord vein
and cryopreserved. After identifying suggestive titles,
the corresponding abstracts were read online to select
articles for printing. Printed full-text articles were
reviewed and their reference lists were used to identify
additional articles and new descriptors. A final search
used Dardik and biograft delimited by Title. Two
articles from periodicals not indexed in the databases
used were also read,9,13 and additional data were
obtained from authors to construct life-tables for two
studies5,14 and to update the follow-up for another
study.6 An anonymous reviewer identified another
article.7Criteria for inclusion
The articles included satisfied the following criteria:
(1) a minimum of 15 allograft bypasses distally
inserted into an infrapopliteal artery; (2) a predomi-
nance (more than half) of these bypasses over bypasses
to the popliteal artery, when both were analysed
together, (3) time-to-event description of graft patency,
(4) type of graft patency clearly indicated, and (5) a
follow-up of a year, at least for some grafts. Meta-
analysis was done separately for four series of CAAs,
10 series of CVAs, three series of CSVAs, and 16 series
of UVAs.2–35 Surgeons from two centers had published
more than one study on allograft bypass grafting, but
the repeated inclusion of bypasses was avoided
(Table 1 and Appendix A). These criteria complied
with the recommendation of broad inclusiveness for
meta-analysis of epidemiological studies.36 A total of
64 papers were identified in the literature and rejected
according to the inclusion criteria.Outcome parameters
The main parameters were secondary graft patency
(SP) and foot preservation (FP) according to rec-
ommended standards.37 Primary graft patency (PP)
was described in only a few studies and therefore it
was not considered further. A stability ratio defined ad
hoc as the ratio between the pooled estimates of
success at 5 years and at 1-month was calculated for
both SP and FP.38
Graft patency was reported as SP in 3 CAA series, 4
CVA series, 1 CSVA series, and 6 UVA series; but it was
reported simply as cumulative patency for 1 CVA
series, 1 CSVA series, and 9 UVA series (Appendix B).
Data from the text were used to infer SP from PP for 1
CVA series, 1 CSVA series, and 1 UVA series.9,20,25 One
CAA study and 3 CVA studies described PP, but it was
interpreted as SP because reoperation for rupture or
aneurysmal degeneration had not been computed as
graft failure.3,7,15,16 Finally, the reported assisted PP
was used as SP for 1 CVA series and 1 UVA series.2,34Study quality
An ideal study should contain the reasons for using
allografts, the proportion of patients requiring these
grafts, life-tables rather than graphs, the 1-month
follow-up interval, an account for loss to follow-up,
and descriptions of PP, SP, and FP. Of particular
relevance is the link between predictive variables and
each life-table. Other relevant items are the proportion
of secondary procedures and tissue loss, the regimens
of postoperative antithrombotic therapy, the pro-
portion of grafts that suffered degeneration or became
infected, and data on further bypasses. A perfect study
would score 14, with a decrease of one point for each
unmet requirement (Table 2, Appendix A).Data extraction
Two junior authors extracted independently the data
from standard life-tables and from survival curves that
showed the number of units at risk for all intervals,
while the senior author retrieved life-table data from
survival curves that showed number of units at risk for
some intervals and from plain survival curves that
omitted any number. All the 17 series of peripheral
allografts and 10 of the 16 series of UVAs were
included in meta-analysis of both SP and FP, whereas 6
UVA series could not be included in the meta-analysis
of FP.13,23,24,30,32,33 The data were obtained from 12 (SP,
nZ8; FP, nZ4) life-tables,5–7,9,12–14,20,31 8 (SP, nZ3; FP,
nZ5) survival curves that showed number of units atEur J Vasc Endovasc Surg Vol 28, November 2004
Table 1. Main features of published allograft series and meta-analysis results
Author Year n 1-year SP (se) 1-year FP (se)
CAA-cryopreserved arterial allografts
Simeo´n et al.7 1998 35 52 (10) 70 (9)
Alonso et al.6 1999 17 93 (8) 94 (8)
Castier et al.4 1999 35 76 (9) 81 (87)
Albertini et al.5 2000 131 57 (5) 84 (3)
Meta-analysis 218 64 (10) 80 (5)
CVA-cryopreserved vein allografts
Ochsner et al.18 1984 75 50 (7) 77 (9)
Harris et al.14 1993 25 37 (13) 76 (18)
Walker et al.19 1993 39 45 (9) 71 (9)
Martin et al.21 1994 115 39 (5) 84 (4)
Posner et al.15 1996 21 48 (13) 62 (12)
Carpenter and Tomaszewski16 1997 40 11 (6) 42 (11)
Leseche et al.17 1997 25 53 (13) 79 (11)
Buckley et al.3 2000 27 84 (7) 89 (7)
Harris et al.20 2001 80 47 (9) 69 (7)
Farber et al.2 2003 240 30 (3) 81 (3)
Meta-analysis 687 48 (6) 78 (5)
CSVA-cold-storaged vein allografts
van Reed Dortland et al.12 1991 51 71 (6) 87 (5)
Rebane et al.10 1997 67 67 (6) 69 (5)
Sacilotto et al.9 1998 39 43 (9) 67 (10)
Meta-analysis 157 64 (10) 76 (8)
UVA-UVAs umbilical-cord vein allografts
Cranley and Hafner28 1982 40 40 (10) 84 (7)
Klimach and Charlesworth22 1983 112 33 (6) 57 (7)
Robison et al.29 1983 32 46 (12) 54 (11)
Raithel et al.30 1984 60 62 (7)
Sciacca et al.32 1984 15 31 (14)
Harris et al.35 1984 60 35 (7) 54 (9)
Guasch et al.13 1985 26 61 (11)
Barry et al.33 1985 18 41 (16)
Largiader et al.23 1985 72 75 (5)
Nevelsteen et al.34 1986 65 65 (7) 64 (7)
Harling et al.24 1987 23 51 (12)
Dardik et al.31 1988 388 54 (3) 77 (3)
Batt et al.25 1990 52 19 (7) 32 (9)
Sommeling et al.26 1990 37 56 (9) 77 (8)
Moody et al.27 1991 80 44 (7) 43 (6)
Dardik et al.8 2002 174 79 (3) 86 (3)
Meta-analysis 1254 54 (5) 70 (6)
Table 2. Summary characteristics of the series included in the meta-analyses
CAA nZ4 CVA nZ10 CSVA nZ3 UVA nZ16
Number of bypasses 218 687 157 1254
Year of publication 1999 1996 1997 1985
(1998, 2000) (1984, 2003) (1991, 1998) (1982, 2002)
Year of beginning 1994 1991 1984 1978
(1991–1995) (1966, 1995) (1978, 1991) (1975, 1990)
Score of quality 11.5 (9, 12) 9.5 (5, 10) 8 (6, 11) 5.5 (3, 10)
Secondary bypass % 75 (60, 100) 70 (27, 94) 50 (36, 67)* 44 (27, 77)*
Claudication % 0 (0, 0) 0 (0, 18)* 0* 0 (0, 8)*
Popliteal bypass % 9 (0, 14)* 9 (0, 36) 0 (0, 13) 0 (0, 45)
Pedal bypass % 0 (0, 12)* 6 (0, 29) 0 (0, 8) 0 (0, 0)
Censored 1-year % 29 (20, 53) 10 (19, 40) 16 (13, 23) 18 (8, 25)
Values are median (range).
* Indicates data not available in all of the series.
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Allograft Bypass Grafting 465risk for all intervals,3,4,16,27,35 9 (SP, nZ5; FP, nZ4)
survival curves that showed this number for some
intervals,12,17,19,21,25,34 and 12 (SP, nZ9; FP, nZ3)
plain survival curves.2,8,10,15,18,22,23,29,32,33 Data of FP
were extracted from both the text and the retrieved
life-table of SP in 4 UVA studies22,26,28,29 and 7
peripheral allograft studies.6,7,14,15,18,19,21 For the
interval between 25- and 36-months, a plain survival
curve from a UVA study admitted two solutions for
SP; the solution that offered the smallest numbers at
risk was used,23 whereas sensitivity analysis inves-
tigated the other alternative. Inclusion in meta-
analysis was restricted to the second interval and
beyond when the 1-month pooled success of SP or
FP was omitted.3,18,23,32Confounding in the original studies
Most studies focused on chronic critical ischaemia, but
4 CVA series and 1 UVA series included a few
bypasses done for claudication; pertinent information
was lacking for 1 CVA series, 1 CSVA series, and 6
UVA series. Rates of secondary bypass ranged from 60
to 100% in the CAA series, from 27 to 94% in the CVA
series, from 33 to 67% in two of the 3 CSVA series, and
from 27 to 77% in seven of the 16 UVA series; pertinent
information was lacking for 1 CAA series, 1 CSVA
series and 9 UVA series. Femoropopliteal bypasses
were included in 3 CAA series, 8 CVA series, 1 CSVA
series, and 1 UVA series. Likewise, pedal bypasses
were included in 2 CAA series, 9 CVA series, and 1
CSVA series; not a single UVA series contained pedal
bypasses (Appendix A).Statistical methods
Random-effects meta-analysis combined monthly
success rates from original series to calculate a
pooled estimate of success for each month of
follow-up. In this calculation, within-study variabil-
ity, between-study variability and between-interval
variability were all considered in the weighting
scheme.39 The product of successive monthly pooled
estimates of success then yielded a pooled measure
of cumulative success for each targeted allograft
(Appendix B). The quantity that a random-effects
meta-analysis estimates is a mean across a universe
of studies and hence across a universe of surgical
centres. Since, the outcome at different surgical
centres varies, a fixed-effects model would not be a
plausible choice.Sensitivity analysis for SP
Bias was possibly introduced because independence
was assumed between graft failure and loss to
follow-up and because 15 of the 17 series of
peripheral allografts also contained popliteal or
pedal bypasses. Based on published data,39,40 the
following assumptions were made to investigate bias
from those sources: (1) the reduced risk of graft
failure for popliteal bypasses and the increased risk
of failure for pedal bypasses were concentrated
within the first month of follow-up, (2) a relative-
risk of graft failure of 0.60 for above-knee popliteal
bypasses, 0.75 for below-knee popliteal bypasses,
and 1.14 for pedal bypasses, (3) the percentage of
censored units representing losses to follow-up was
22% in the first month, 47% from the second through
the sixth month, and 18% from the seventh through
the twelfth month, and (4) 60% of the grafts
considered as lost within the first year of follow-up
represented additional failures. Sensitivity analysis
also investigated publication bias and measured the
impact of a study for which SP was subjectively
inferred from the reported PP. Fixed-effects meta-
analysis was performed for illustration.Reference meta-analysis of PTFE grafts
The electronic databank of a published meta-analysis
from our group was investigated.39 There were 1379
PTFE grafts with adjunctive procedures, which came
from 23 series described in 19 studies. That meta-
analysis was used in a graphical comparison of
outcomes with the present meta-analyses.Results
Differences between sets of series
UVA studies were older on average, contained a
greater number of grafts, were scored the lowest for
quality, and did not contain a single pedal bypass.
Although information regarding risk variables was
incomplete, the available data showed that the UVA
series contained less women, less diabetic patients,
and less secondary bypasses (Table 2).Meta-analysis of UVAs
The meta-analysis of UVA series included a greater
number of studies. The pooled estimates (standard-
error) of SP and FP were 76% (3%) and 83% (4%) atEur J Vasc Endovasc Surg Vol 28, November 2004
M. Albers et al.4661-month, 54% (5%) and 70% (6%) at 1-year, and 30%
(9%) and 55% (4%) at 5-years, respectively. The
pooled survival curves of SP and FP were diver-
gent, with a difference of 25% at 5-years (Figs. 1 and
2). The median difference between FP and SP at 1-
year follow-up was 15% for four series that
contained only one UVA bypass per limb and 16%
for six series that contained two or more UVA
bypasses per limb. Study quality, which correlated
moderately with year of publication (Pearson rZ
0.64; P!0.008), did not correlate with 1-year SP
(Pearson rZK0.09).Fig. 2. Pooled survival curves of foot preservation (FP) for
cryopreserved arterial allografts (CAA) (squares), cryopre-
served vein allografts (CVA) (circles), CSVAs cold-storaged
vein allografts (CSVA) (triangles), UVAs umbilical-cord vein
allografts (UVA) (thick gray line), and PTFE grafts (thick
black line).Meta-analysis of peripheral allografts
In the meta-analysis of CVA series, the pooled
estimates (standard error) of SP and FP were 90%
(3%) and 94% (2%) at 1-month, 48% (6%) and 78%
(5%) at 1-year, and 19% (13%) and 60% (11%) at 5-
years. Similarly, meta-analysis of CAA series showed
pooled estimates of SP and FP of 89% (5%) and 93%
(4%) at 1-month, 64% (10%) and 81% (5%) at 1-year,
and 21% (10%) and 68% (9%) at 5-years (Figs. 1 and
2). In the meta-analysis of CSVA series, the corre-
sponding pooled estimates were 92% (5%) and 89%
(6%) at 1-month, 64% (10%) and 76% (8%) at 1-year,
and 24% (19%) and 39% (29%) at 5-years, respectively;
SP was lower than the pooled FP in the first 3-months
only (Figs. 1 and 2). Overall, the median difference
between FP and SP at 1-year follow-up was 15% for
10 series that contained only one peripheral allograft
bypass per limb and 27% for seven series that
contained two or more peripheral allograft bypasses
per limb.Fig. 1. Pooled survival curves of secondary graft patency (SP)
for cryopreserved arterial allografts (CAA) (squares), cryo-
preserved vein allografts (CVA) (circles), CSVAs cold-
storaged vein allografts (CSVA) (triangles), UVAs umbili-
cal-cord vein allografts (UVA) (thick gray line), and PTFE
grafts (thick black line).
Eur J Vasc Endovasc Surg Vol 28, November 2004In CVA series, the scores of study quality correlated
strongly with year of publication (Pearson rZ0.74; P!
0.02) but, as for UVAs, they did not correlate with 1-
year SP rates (Pearson rZK0.12). Because only a few
studies were available, the assessment of correlations
would be meaningless in both CSVA series and CAA
series.Comparison of meta-analyses
A graphical display of pooled survival curves of SP
showed that the reference PTFE grafts occupied the
uppermost position beyond the 7-month follow-up
and that the curve for UVAs eventually crossed up
across the curves for all peripheral allografts,
ending up more favorable. The latter were initially
divergent, but tended to convergence beyond 24-
months (Fig. 1). The pooled survival curve of FP
for PTFE grafts occupied the second position,
below the curve for CAAs and above the curves
for CVAs UVAs and CSVAs, in that order (Fig. 2).
When only allografts were compared, CSVAs
performed the best for SP and the worst for FP.
The 5-year patency stability ratio was 23% for
CAAs, 22% for CVAs, 26% for CSVAs, 40% for
UVAs, and reached 48% for the reference PTFE
grafts. Overlapping of 95% confidence intervals for
the pooled SP was generally extensive and tended
to increase with time, but it did not occur at 1-
month in the comparison between CAAs and UVAs
nor at 3-months in the comparison between CSVAs
and UVAs.
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Sensitivity analysis for distal anastomosis and loss to
follow-up decreased the 5-year pooled SP by 3% in the
meta-analysis for CAAs, and by less than 2% in the
other meta-analyses.
The exclusion of 1 CAA series, 4 CVA series and 1
UVA series that described PP or assisted PP decreased
the corresponding 5-year pooled SP by 0.8, 3 and 0.8%,
respectively. However, the exclusion of the most
successful UVA graft series decreased the 5-year
pooled SP by 5% and the corresponding graft stability
ratio by 6%. Alternatives in the reconstruction of a life-
table for a UVA series decreased the 5-year pooled SP
by 0.9%.
For series with less than 50 grafts, the 1-year SP was
lower than the corresponding pooled estimate in six of
the nine series of peripheral allografts and in six of the
seven series of UVAs, which did not suggest the
presence of publication bias in its usual form of small
series with worse outcomes remaining unpublished.
Admittedly, 41 UVAs performed from 1986 through
1989 were not included in a large study.8Fixed-effects modeling
The fixed-effects model increased the 5-year pooled SP
by 3% for CAAs, 6% for CVAs, and 3% for both CSVAs
and UVAs. With this modelling strategy, 95% confi-
dence intervals for the 1-month pooled SP did not
overlap in the comparison between UVAs and each
peripheral allograft.The contribution of between-interval variances
When between-interval variances were not used, the 5-
year pooled SP increased by 0.4% for CAAs whereas it
decreased by 0.6% for UVAs, 0.5% for CVAs, and 0.3%
for CSVAs. However, the difference in 1-year pooled
SP between CAAs and UVAs increased by 3%.Discussion
This study followed a plan of overviewing studies on
bypass revascularisation of infrapopliteal arteries,
which began with a meta-analysis of PTFE grafts that
now served for informal comparison of outcome
parameters.39 Since, SP better reflects the fate of
arterial reconstructions and is usually described
precisely, this parameter is a natural target to meta-
analysis aimed to assess outcomes for different graft
materials. On the other hand, FP describes the fate ofrevascularised limbs, which does not depend solely on
graft patency. Besides, being inflated by the inevitable
inclusion of some patients at low risk of amputation,
FP does not mean absence of critical ischaemia nor
does it always reflect the effects of a single graft per
limb. Not surprisingly, often the primary literature
omitted FP, mentioned it briefly, or measured it
inadequately.
Since, the confidence intervals for the pooled
estimates overlapped so extensively, there are prob-
ably no statistically significant differences between the
graft types. Although these differences are explainable
by chance, surgeons must rely on available data and
search for trends in these data.
A superior early SP for peripheral allografts
compared to UVAs likely was the consequence of a
thinner wall and better handling characteristics, but
since peripheral allografts were on average 10 years
more recent, improved surgical skills over time should
also be considered as a factor. On the contrary, the fate
of initially patent grafts was less favorable for
peripheral allografts, probably because of immuno-
logical rejection, which seemingly does not interfere at
the same extent with glutaraldehyde-tanned UVAs.
Interestingly, CSVAs showed better SP and worse FP
than cryopreserved allografts, possibly because of
inclusion of patients with more advanced limb
ischaemia in meta-analyses for CSVA series. That the
pooled SP was lower than the pooled FP at 1-month
indicated that many CSVA patients were beyond the
scope of limb revascularisation. In addition, the small
gap between the survival curves of SP and FP revealed
a close dependence of FP on a functioning CSVA
bypass, which is typical of end-stage vascular disease.
However, even the provisional acceptance of any
advantage for CSVAs must be tempered by a lack of
biological plausibility, insufficient data and possible
hidden bias. Preventing transmission of viral infection
remains a major challenge, to the point that using
CSVAs became arguably unethical.5
Longer storage of cryopreserved allografts allows
a time interval for better screening of viral agents,5
but even the avoidance of bacterial and fungal
infection remains problematic.2 Since, these allografts
had superior early SP, they may be useful in
overcoming critical ischaemia for a short time,
especially when a pedal bypass is indicated or the
risk of wound infection is increased. Presumably in
such a situation UVAs, which include a surrounding
synthetic mesh, and PTFE grafts are useless. Cryo-
preserved allografts may benefit from standard
antirejection therapy,3 but this is hardly acceptable
for the aged patient with severe atherosclerosis,
ischaemic, and often infected ulcers. Since, repeatEur J Vasc Endovasc Surg Vol 28, November 2004
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series that included 49% of the CVAs,2,21 and in one
series that contained 60% of the CAAs,5 the wide
gaps between the pooled survival curves of SP and
FP for cryopreserved allografts were misleading. On
the other hand, the acceptable FP rates indicated that
a policy of using these allografts to avoid major
amputation may be more effective than a strategy
that resorts to UVAs.
When compared to meta-analyses of peripheral
allografts, the meta-analysis of UVAs showed a
lower early pooled SP, but the pooled survival
curve of 16 UVA series crossed the pooled
survival curve of 10 CVA series relatively early
in follow-up. Although the time of crossing the
curves of CAAs and CSVAs was delayed until 31-
and 48-months, respectively, the meta-analyses for
these peripheral allografts included only a few
studies. These findings reflect a higher patency
stability for UVAs which was resistant to exclu-
sion of the most successful study and to
sensitivity analysis done under extreme assump-
tions. This property of the UVA may reflect a
lesser degree of immunological rejection and also
an inherent resistance to thrombosis, as already
found for this graft in above-knee femoropopliteal
revascularisation.1 Since, the pooled FP was
uniformly lower for UVAs than for cryopreserved
peripheral allografts, with no crossing points in
their pooled survival curves, FP was also influ-
enced by causes other than SP and patency
stability. Less opportunity for, and less inclination
towards repeat revascularisation in the past are
plausible causes.
Of note, Dardik’s et al.8 achieved high success
with UVAs, and the results were only inferior to
two series of PTFE grafts.41,42 The improvement
achieved in that singular UVA series was a
consequence of both increased SP and increased
patency stability. Indeed, sensitivity analysis that
excluded that study decreased the 1-month SP by
5.0% and the 5-year patency ratio by 6.0%.
Although it remains unclear whether the most
important factor were the use of a distal
arteriovenous fistula, oral anticoagulation, or new
graft technology that eliminated problems of graft
degradation,8 the results of that study represent a
favorable prospect for UVAs.
The future seems less uncertain for peripheral
allografts. In a comparison with the reference meta-
analysis of PTFE grafts, the pooled SP was equivalent
for CSVAs until 2-years of follow-up, although this
measure was less successful for cryopreserved allo-
grafts. In contrast, the pooled FP for the latter wasEur J Vasc Endovasc Surg Vol 28, November 2004encouraging, probably as an effect of repeat revascu-
larisation procedures. In addition to strategic use in
preventingmajor amputation, peripheral allografts are
especially useful for in situ replacement of infected
prosthetic grafts.43
In the assessment of graft patency, it is widely
recognised that graft material, degree of ischaemia,
level of distal anastomosis and secondary bypass are
strong predictive variables. All except the latter were
naturally restricted by design thus providing an
effective protection against bias. Since, UVA series
did not contain pedal bypasses and apparently
included fewer secondary bypasses, UVA patients
possibly had a lower underlying risk, which only
reinforces the evidence against UVAs.
Most of the potential sources of bias in the
original studies proved to be unfounded and did
not impair internal validity of the meta-analyses.
First, UVA studies as older studies followed meth-
odological standards of the past. Overestimation of
the pooled SP was a possibility because of the use of
‘cumulative patency,’ but this expression likely
described SP in those studies. Still because UVA
studies were older, their lower scores of quality do
not mean unreliable assessment of outcomes. Indeed,
there was no correlation between quality score and
1-year SP neither in peripheral allograft series nor in
UVA series. Second, the inclusion of a series20 for
which SP was subjectively inferred from PP
decreased the pooled SP by only a little, 1.4% at 5-
year follow-up. Third, inclusion of popliteal and
pedal bypasses in most series of peripheral allo-
grafts, and loss to follow-up generally, were concerns
that sensitivity analysis under extreme assumptions
eliminated. However, at least three limitations
should be recognised. First, these were meta-analyses
of observational studies, so the possibility of bias
increases. Second, the life-tables reconstructed were
but an approximation in 15 of the 33 studies used in
meta-analysis of SP. Third, often it was unclear
whether events related to graft degradation counted
as graft failures.
Bias from sources other than the original studies
was also unlikely. Publication bias was not detected,
though several grafts were omitted in the most
successful series of UVAs. Random-effects modelling
avoided overestimation of parameters and undue
precision in all the meta-analyses. In conclusion,
meta-analysis indicated that graft patency after
distal bypass surgery is poor for allografts generally.
While the use of peripheral allografts in repeat
attempts at revascularisation is a valid strategy to
prevent major amputation, a precise role for UVAs
remains uncertain.
Allograft Bypass Grafting 469Appendix A. Assessment of survival analysis and
quality scores in 33 series of allograft bypasses
Author Claudication
(%)
Secondary
bypass
(%)
Popliteal/
pedal
bypass (%)
Life-
table
CAA-cryopreserved arterial allografts
Simeo´n7 0 60 ? C
Alonso6 0 75 7/0
Castier4 0 74 14/0
Albertini5 0 100 0/13 C
CVA-cryopreserved vein allografts
Ochsner18 4 83 36/1
Harris14 0 76 8/4 C
Walker19 13 87 7/3
Martin21 18 94 12/1
Posner15 0 62 9/29
Carpenter16 0 90 8/15
Lese`che17 0 64 0/8
Buckley3 0 27 0/0
Harris20 ? 46 31/9 C
Farber2 2 59 0.5/9
CSVA-cold-storaged vein allografts
Van Reed
Dortland12
? ? 0/0 C
Rebane10 0 33 37/0
Sacilotto9 0 67 13/8 C
Cranley28 0 ? 0/0
UVA-UVAs umbilical-cord vein allografts
Klimach22 0 27 0/0
Robison29 0 44 0/0
Raithel30 ? ? 0/0 C
Sciacca32 0 ? 0/0
Harris35 8 77 45/0
Guasch13 ? ? 0/0 C
Barry33 0 ? 0/0
Largiader23 ? ? 0/0
Nevelsteen34 0 29 0/0
Harling24 0 ? 0/0
Dardik31 4 ? 0/0 C
Batt25 0 42 0/0
Sommeling26 ? ? 0/0
Moody27 0 54 0/0
Dardik8 ? 47 0/0 C
CC: use in all or most patients; C: use in few patients; -: no use; ?: not inform1-mo
intervalLosses
described
(%)Eur JCensored
1-year (%)Vasc EndovasMeasuresc Surg Vol 28Risk-
set, NovemQuality
scoreC C 20 SP, FP 10C 53 PP, SP C 11C 34 PP, SP, FP C 12C C 23 PP, SP 923 CPR C 5C C 28 SP C 10C 10 PP, SP C 9C 10 PP, SP, FP C 11C 19 SP C 8C 13 SP, FP C 9C 36 SP, FP C 10C 15 SP, FP C 10C 40 PP, FP C 9C 20 PP, SP, FP C 1216 CPR 6C 4 SP 8C 23 SP, FP C 11C 20 CPR 4C C 21 CPR C 7C 25 CPR 5C C 12 CPR 520 CPR 3C 15 CPR, FP C 7C 15 SP 7C 22 CPR 48 CPR 4C 20 PP, SP, FP 5C 22 CPR 5C 14 PP, SP, FP 7C 15 PP, SP, FP C 10C 14 SP 6C 25 SP, FP C 816 PP, SP, FP C 9ed; C: presence of required item; CPR refers to cumulative patency rate.Appendix B. Statistical notes
The Strategy
A strategy was constructed to combine survival data
because different grids of time intervals had been used
in the series reviewed. In the first step, units of analysis
(grafts or limbs) censored at intervals greater than 1-
month were redistributed in equal quantities at 1-
month intervals. Next, the numbers of failed grafts or
lost feet were obtained for intervals of 1-month; thiswas done by using the units at risk at the start of an
interval, the redistributed censored units, and the
interval hazard rates. Kaplan–Meier success rates were
then calculated for each series and each month of
follow-up and used as treatment effects. This approach
assumed constant hazard rates within long time
intervals and the mid-point of such intervals as the
survival time for censored units as is usual in actuarial
life-tables.
In the second step, an ad hoc procedure was used to
obtain a within-series variance (s2) for each monthlyber 2004
M. Albers et al.470success rate in each series; next, a between-series
variance (t2) was calculated for each month and a
between-interval variance (d2) was calculated for each
series.
In the third step, random-effects modelling was
used to obtain pooled measures of treatment effect for
each month of follow-up and it was assumed that the
treatment effect in each study varies monotonically
with time. Random-effects modelling assumes that
included studies are a random sample of the universe
of studies.
Finally, the product of successive monthly pooled
measures of treatment effect yielded pooled measures
of cumulative success, for which approximate confi-
dence intervals were calculated.The statistical problem
Since, this meta-analysis dealt with case series studies,
the problem here was one of parameter estimation, not
hypothesis testing. Consequently, pooled measures
were estimated and standard-errors were calculated
for them. It would not be possible to derive P-values
because formal statistical comparisons were not
pursued.Interval success rate
For each series i and each month j of follow-up, an
interval success rate, lij, was determined as follows:
lijZ
1K fij
nij
;
where fij is the number of failed grafts and nij is the
number of grafts at risk.Within-series variance
Since, lij was frequently 1.00 or close to 1.00, an ad hoc
procedure was applied to calculate the within-series
variance, sij
2, as follows:
s2ijZ
ðfijC1ÞðnijK fijC1Þ
ðnijC2Þ3Between-series variance
For each month j (jZ1,2,.,60) the between-seriesEur J Vasc Endovasc Surg Vol 28, November 2004variance, tj
2, was calculated as follows:
t2j Z
f½P niðliKli$Þ2=
P
nigkj
ðkjK1Þ
where, in the target month j, li is the success rate in
study i(iZ1,2,.,kj), li$ is the average for li, ni is the
number of units at risk in study i, and kj is the number
of series available.Between-interval variance
For each series i the between-interval variance, di
2, was
calculated as follows:
d2j Z
½PðljK1CWjÞ2
ðtiK1Þ ;
where, in the target series i, nj is the number of grafts at
risk at month j, lj is the success rate at month j, Wj is
theWeibull hazard rate at month j, and ti is the number
of time intervals available.
The Weibull model uses the shape parameter (a)
and the scale parameter (b) to describe the hazard
function according to the equation below:
WðtÞZabðatÞðaK1Þ:
The parameters a and bwere calculated for each study
separately and were obtained by a linear regression of
ln½Kln SðtÞ on ln t, in which ln refers to natural
logarithms and S(t) is the survival estimate at time t.
The slope of the regression line is an estimate of a and
the ln t intercept an estimate ofKln a.Weighting and combining the lij
Let uij be the weight attributed to each lij. When using
random-effects modelling, it follows that:
uijZ
1
ðs2ijCd2i Ct2j Þ
:
A summary effect estimate, Lj, was obtained for
interval graft patency in month j (jZ1,2,.,60) as
follows:
LjZ
P
liuiP
ui
;
where li is the success rate in the target month j, and ui
is the weight attributed to li.
Such estimators Lj will be consistent and approxi-
mately normal, and are derived based on the fact that
the estimators for each series are approximately
normal with an estimable variance. Finally, the
Allograft Bypass Grafting 471product of successive Lj yielded Gj, the summary
estimate for cumulated success at month j.Variance and confidence interval for Gj
After properly corrected, Kaplan–Meier estimates and
their respective variances in the original series were
used to obtain the variance of Gj. This was done by
using again random-effects modelling in a way similar
to that of obtaining Lj. The difference was that Peto’s
within-series variances in study i at month j and tj
2
were summed up to weigh the Kaplan–Meier esti-
mates at month j. A summary Kaplan–Meier estimate,
Kj, and its variance, V{Kj}, were thus obtained for
month j. Since, Kj and Gj differed a little, the variance
of Gj, V{Gj}, was obtained as follows:
VfGjgZ
VfKjg½L2j ð1KLjÞ
½K2j ð1KKjÞ
:
Confidence intervals for Gj were then obtained by
using V{Gj}.References
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